Abstract
Alzheimer’s disease (AD) continues to threaten aged individuals and health care systems around the world. Human beings have been trying to postpone, reduce, or eliminate the primary risk factor for AD, aging, throughout history. Despite this, there is currently only symptomatic treatment for AD and this treatment is limited to only a handful of FDA approved AD drugs.
Alzheimer’s disease (AD) continues to threaten aged individuals and health care systems around the world. Human beings have been trying to postpone, reduce, or eliminate the primary risk factor for AD, aging, throughout history. Despite this, there is currently only symptomatic treatment for AD and this treatment is limited to only a handful of FDA approved AD drugs.
No Figures found in article.
Dr. Rick Brucato. 2020. “. Global Journal of Medical Research – F: Diseases GJMR-F Volume 20 (GJMR Volume 20 Issue F6): .
Crossref Journal DOI 10.17406/gjmra
Print ISSN 0975-5888
e-ISSN 2249-4618
A Comparative Study of the Effeect of Promotion on Employee
The Problem Managing Bicycling Mobility in Latin American Cities: Ciclovias
Impact of Capillarity-Induced Rising Damp on the Energy Performance of
Digital Diasporas: Rethinking Belonging, Space, and Citizenship in the Digital
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
